Overview

Kerem Therapeutics is a clinical stage biotechnology company that is currently advancing a novel cell-based immunotherapy to treat a wide variety of solid tumor indications. Our co-founders were responsible for the initial invention, development and clinical testing of RBI-001 against solid tumors. The transient upregulation of MYC protein in anergic lymphocytes is a key element in reversing their non-responsiveness to tumors. In addition, the natural turnover of the proteins we introduced into the cells provides a measure of safety and control over the powerful tumoricidal activity we activate with our groundbreaking approach. RBI-001 has already produced some life- changing results in patients with Non-small lung cell carcinoma, metastatic colorectal cancer, metastatic breast cancer, and hepatocellular carcinoma. We have also observed the resolution of metastatic lesions in the brains of some of these patients. These tumors are normally considered “immunologically cold” malignancies that don’t respond to immune-based therapies. RBI-001 appears to alter the immune reactivity of these “cold” tumors, thereby rendering them immunologically reactive. RBI-001 is conditionally approved in Japan by the Japanese Ministry of Health, Labor and Welfare under a self-pay track. The therapy has been under continuous use in clinics in the Tokyo and Sendai area for cancer, chronic viral disease and more recently for boosting of the immune system.